Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2024.0821 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Atsumasa Komori und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Nagasaki University Graduate School of Biomedical Sciences, Omura, Nagasaki, Japan. Hauptthemen laut MEDLINE: Hepatitis, Autoimmune, Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: GSK, Kowa Company.
Abstract (Originalsprache)
Patients with hard-to-treat autoimmune hepatitis (AIH) or primary biliary cholangitis (PBC) are defined a posteriori as those who do not show a sufficient response or are intolerant to pharmacological treatments, thus not achieving biochemical surrogate endpoints that are associated with long-term liver-related-event-free survival. The absence of a recently harmonized definition of ‘complete biochemical response within 6 months (CBR≤6M)’, which is defined as the normalization of serum transaminase and IgG levels below the upper limit of normal at ≤6 months after treatment initiation, is regarded as hard-to-treat AIH. The implementation of CBR≤6M, in turn, has been facilitating clinical trials, e.g., between azathioprine and mycophenolate mofetil, to reconsider appropriate first-line steroid sparing agents, leading to a reduction in the number of hard-to-treat AIH cases. Regarding PBC, one of the disseminated definitions of hard-to-treat patients is the absence of POISE criteria, which are evaluated at 12 months with serum alkaline phosphatase and bilirubin levels, after the introduction of ursodeoxycholic acid. Hard-to-treat PBC not meeting the POISE criteria has very recently been the target population for the U.S. FDA-approved second-line drugs, elafibranor and seladelpar. In future pharmacological treatment of AIH and PBC, the primary objective for AIH is likely to focus on lowering the number of hard-to-treat patients with personalized steroid sparing treatment regimens. A challenging goal in PBC treatment is the further optimization of treatment surrogate endpoints, even to the stricter alkaline phosphatase normalization, with which an indication of second- or later-line drugs might be expanded, but could ultimately lengthen patients’ long-term survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, Nagasaki University Graduate School of Biomedical Sciences, Omura, Nagasaki, Japan.
- Hepatology Unit, NHO Nagasaki Medical Center, Nagasaki University Graduate School of Biomedical Sciences, Omura, Nagasaki, Japan.
- Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Omura, Nagasaki, Japan.
Förderung
- GSK
- Kowa Company
Zitieren
APA
Komori, A., & Kugiyama, Y. (2025). Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0821
Vancouver
Komori A, Kugiyama Y. Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0821
BibTeX
@article{Komori2025,
author = {Komori, Atsumasa and Kugiyama, Yuki},
title = {Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2024.0821}
}
EUVIMED